S33 - Progressive MS Therapeutics

Event Time: Wednesday April 26, 2017 3:30 pm to 5:30 pm
Topic(s): MS and CNS Inflammatory Disease
Description: A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts.
Completion Message:
CME Credits: 2
Core Competencies:

Abstract Presenters

Start Time Pub. Title Presenter
3:54 PM 003 Retinal Nerve Fiber Layer Thickness defines Multiple Sclerosis Patients at Risk of Future Disease Progression Pablo Villoslada
Dr. Villoslada has nothing to disclose.

4:06 PM 004 Efficacy Results from the Phase 2b SYNERGY Study: Treatment of Disabling Multiple Sclerosis with the Anti-LINGO-1 Monoclonal Antibody Opicinumab Michelle Mellion, MD
Dr. Calabresi has nothing to disclose.

4:18 PM 005 Development of a sensitive Outcome for Economical Drug Screening for Progressive Multiple Sclerosis Peter Kosa, PhD
Dr. Kosa has nothing to disclose.

4:30 PM 006 The Association Between Confirmed Disability Progression and Patient-Reported Fatigue in PPMS Patients in the ORATORIO study Deborah Miller, PhD
Dr. Miller has nothing to disclose.

4:42 PM 007 Safety and Tolerability of Siponimod in Patients with Secondary Progressive Multiple Sclerosis: Robert Fox, MD, FAAN
Dr. Fox has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allozyne, Avanir, Biogen Idec, Novartis, Questcor and Teva Pharmaceutical Industries. Dr. Fox has received research support from Biogen and Novartis.

4:54 PM 008 Long-term Outcomes in Patients with Progressive MS with Relapses: Analysis of TEMSO and TOWER Extension Data Flavia Nelson
Dr. Nelson has nothing to disclose.

Ready to register for the 2018 AAN Annual Meeting?

Register Now

Related Courses